scholarly journals Randomized phase III trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis

2019 ◽  
Vol 30 ◽  
pp. v386-v387
Author(s):  
M. Uemura ◽  
Y. Tomita ◽  
H. Miyake ◽  
S. Hatakeyama ◽  
H.-O. Kanayama ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Subgroup Analysis ◽  
Renal Cell ◽  
Phase Iii ◽  
Advanced Renal Cell Carcinoma ◽  
Line Treatment ◽  
First Line ◽  
Phase Iii Trial ◽  
First Line Treatment

scholarly journals Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma

2020 ◽  
Vol 36 (9) ◽  
pp. 1507-1517
Author(s):  
Arielle G. Bensimon ◽  
Yichen Zhong ◽  
Umang Swami ◽  
Allison Briggs ◽  
Joshua Young ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cost Effectiveness ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document